Enduring the Downturn

This was intended to be a "good news/bad news" report on the current state of biotechnology hiring. As it turns out, the bad news is that I can't find anything for the "good" piece of that equation. With the war adding to the general insecurity that many feel, the job market isn't a real pleasure to be a part of right now. As a biotechnology headhunter, I've staffed young companies and helped them manage the development of new medicines. Now these same firms are in need of a fix themselves, a

David Jensen
May 4, 2003

This was intended to be a "good news/bad news" report on the current state of biotechnology hiring. As it turns out, the bad news is that I can't find anything for the "good" piece of that equation. With the war adding to the general insecurity that many feel, the job market isn't a real pleasure to be a part of right now.

As a biotechnology headhunter, I've staffed young companies and helped them manage the development of new medicines. Now these same firms are in need of a fix themselves, as they face the single worst crunch of their existence: a one-two punch from the economy and turned-off investors. Every day I hear reports of companies cutting back, laying off, or just going out of business. Industry insiders are split regarding how long this retrenching period will last but they are unanimous as to what will result: closures and consolidations...